ERBB2 and invasive breast carcinoma: Participants across disciplines stated that the Choosing Wisely recommendation led them to consider SLNB omission; however, perspectives varied regarding the lack of specificity of the recommendation (which states, “do not routinely use SLNB in clinically node-negative women ≥70 years of age with early-stage HR+, HER2- invasive breast cancer”7) (Table 3).